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Editorial
Filling the Gap: Toward
a Disease Activity Tool
for Systemic Juvenile
Idiopathic Arthritis
Systemic juvenile idiopathic arthritis (sJIA) accounts for
5%–15% of all children with chronic arthritis seen in Europe
and North America, but is much more common in Asia, with
reported frequency in India and Japan as high as 25% and
50%, respectively1. It is rather distinct from the other forms
of JIA, owing to the association of arthritis with peculiar
extraarticular symptoms, which include high-spiking fever,
erythematous macular rash, diffuse lymphadenopathy,
hepatosplenomegaly, and serositis, especially pleuritis and
pericarditis2,3. Arthritis may be absent at onset and develop
during the disease course, weeks, months, or rarely, years
after the occurrence of systemic manifestations. Character-
istic laboratory features include anemia (usually hypo-
chromic and microcytic), leukocytosis, thrombocytosis,
elevated immunoglobulins, increased erythrocyte sedimen-
tation rate (ESR) and C-reactive protein (CRP), and hypoal-
buminemia. Children with sJIA are uniquely susceptible to
develop a potentially fatal hyperinflammatory complication
known as macrophage activation syndrome4.
    Regular measurement of the level of disease activity in
children with sJIA through the application of well-established
tools is important in monitoring the disease course over time
and in assessing the effectiveness of therapeutic interven-
tions. However, clinical instruments specifically validated for
use in sJIA are lacking. In recent randomized controlled trials
of sJIA, the American College of Rheumatology Pediatric 30
criteria have been adapted for measuring therapeutic response
by adding, besides the 6 core set variables, the demonstration
of the resolution of fever (≥ 38°C) during the week preceding
the evaluation5,6 or of the absence of fever (≥ 38.5°C) in the
previous 2 weeks, and the reduction of systemic cortico-
steroid dosage by at least 10% from baseline in patients
taking these medications7. Published criteria for clinically
inactive disease8,9 and minimal disease activity10 are suitable
for use in sJIA. However, they are intended to define a
particular disease activity state and do not allow quantitative
estimation. In the last decade, the Juvenile Arthritis Disease
Activity Score (JADAS) has gained increasing popularity
for the measurement of the level of disease activity in
children with JIA11,12,13. However, although the JADAS has
been used in studies of sJIA14, it has been validated only in
children with oligoarthritis and polyarthritis, including sJIA
without extraarticular features, but not in children with sJIA
and active systemic manifestations15.
    Because systemic symptoms have a major influence on a
child’s well-being and play a key role in driving therapeutic
decisions, any instrument used to assess the level of disease
activity in sJIA must incorporate their assessment. Although
these manifestations are partially recorded by the physician’s
and parent’s/child’s global assessment scales, there is
currently no tool that enables their specific measurement. In
the past, quantitative systemic feature scores have been
devised16,17 (Table 1), but none have been widely embraced.
    In this issue of The Journal, Limenis, et al18 report the
results of the final phase of a 3-step process aimed to develop
a tool to measure disease activity in sJIA. In the first step,
292 items relevant to disease activity were generated through
interviews with 14 children with sJIA and their parents. The
second stage consisted of a Delphi survey of international
experts, which led to identification of the 29 most important
indicators of disease activity in sJIA. The final step described
in the present article was organized into the following 3
parts: (1) scrutiny of the metrologic performances of the 29
items in 57 patients recruited in 3 Canadian centers; (2)
resurvey of experts with review of the data obtained in the
validation study; and (3) proposal of a core set of disease
activity measures.
    A very detailed methodology was used to score disease
activity in the study patients, which included an 18-item
patient questionnaire, a 12-item parent questionnaire, the
Childhood Health Assessment Questionnaire of physical
disability, and a series of physician evaluations, consisting
of the global assessment of disease activity (PGA)
measured on a 10-cm visual analog scale (VAS), 10 clinical
See sJIA disease activity measures, page 115
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and laboratory items, and questions regarding changes to
medications.
    The PGA was used as a criterion standard for the study,
and for some analyses patients were dichotomized into those
with mildly active or inactive disease and with moderately to
severely active disease, based on whether the VAS for the
PGA was < 1.5 or ≥ 1.5, respectively. This cutoff was chosen
arbitrarily because it was meant to be “clinically sensible”
and allowed dividing the patients into 2 roughly equal groups. 
    For continuous variables (e.g., active joint count), the
strength of association with the criterion standard was first
determined by calculating Pearson correlation coefficient.
Then, receiver-operating characteristic curves (ROC) were
created for each item to calculate the optimal cutoff value and
the overall diagnostic value. For dichotomous variables (e.g.,
presence or absence of rash), sensitivity and specificity were
computed in relation with the dichotomized criterion
standard. The results of this analysis were used to calculate
the likelihood ratios for a positive test.
    The results of the validation study were subsequently
submitted to the same group of international experts surveyed
in the earlier step of the process. Based on the review of these
data and their own judgment, the experts were asked to select
the 10 items that they felt were most relevant to disease
activity. The PGA was excluded from the survey because it
was used as a criterion standard. The response rate of 154/187
(82%) was remarkable. 
    The final core set of items for measuring disease activity
in sJIA was set up by selecting the outcome variables that
were assigned the highest number of expert votes and had a
minimum Pearson correlation of 0.5 with the criterion
standard. The core set includes 6 clinical measures (PGA,
child’s and parent’s global assessments, active joint count,
rash, and fever) and 3 laboratory tests (ESR, CRP, and
hemoglobin). For continuous variables, the cutoff points
calculated with the ROC method in validation analyses that
correspond to moderately or severely active disease are
provided.
    The outcome variables included in the core set proposed
by Limenis, et al appear appropriate because they are part of
the classic indicators of disease activity in sJIA and were
agreed upon by a large number of international expert
pediatric rheumatologists. There is, however, a problem with
the cutoff points for moderate/high disease activity, which
seem too mild for a highly inflammatory illness such as sJIA.
Examples are the values for CRP (> 5.5 mg/l), hemoglobin
(< 119 g/l), and parent’s and child’s global assessments 
(> 0.9 cm and > 0.4 cm, respectively). 
    This shortcoming is partly due to the study design and the
characteristics of the study population. Patients were
recruited in routine followup visits rather than at initial
presentation or during times of disease flare, and as a result
had a low prevalence of systemic manifestations. Indeed,
only 3 of them had fever, only 7 had rash, and chest pain,
lymphadenopathy, splenomegaly, and hepatomegaly were
each detected in only 1 patient (although all different
patients). The paucity of extraarticular symptoms explains
the poor sensitivity of these variables for higher disease
activity. Another limitation of the Limenis, et al analysis is
the use of a 2-week time frame to assess fever and rash,
which appears too lengthy to evaluate these features in
conjunction with disease activity at a particular clinic visit.
In our opinion, a 1-week time frame would be more appro-
priate. As discussed, the cutoff chosen to dichotomize the
PGA is arbitrary and subjective and not supported by liter-
ature evidence. A further problem with the proposed core set
is that it only enables distinction of patients with inactive
disease or mild disease activity from those with moderate or
high disease activity, but is not suitable to quantify the
absolute level of disease activity.
    Despite these limitations, the authors are to be
commended for accomplishing a valuable research effort and
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Table 1. Composition and scoring of systemic feature scores published in the literature. 
Woo, et al16                                                         Vojinovic, et al 17
Feature                                                      Score                Feature                                                          Score
Fever*                                                                              1                    Fever†                                                                                   1
Rash                                                             1                    Rash                                                                 1
Cervical lymphadenopathy                          1                    Lymphadenopathy                                           1
Axillary lymphadenopathy                          1                    Hepatomegaly or splenomegaly                      1
Inguinal lymphadenopathy                          1                    Serositis**                                                                           1
Hepatomegaly                                              1                    ESR ≥ 20 mm/h                                               1
Splenomegaly                                              1                    CRP ≥ 10 mg/l                                                 1
Serositis**                                                                      1                    WBC count ≥ 12 × 109/l                                  1
                                                                                          Hemoglobin ≤ 11 g/dl                                      1
                                                                                          Platelet count ≥ 400 × 109/l                             1
Score range                                                0–8                  Score range                                                   0–10
*At the assessment visit or in the 24 hours preceding the assessment visit. ** Pericarditis, pleuritis, or peritonitis.
† As documented in a diary. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; WBC: white blood
cell.
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for providing a core set of disease activity measures that may
constitute the basis for the future development of response
criteria specific for sJIA. A further important initiative in this
area of research, which is currently in progress, is the inter-
national collaborative effort aimed to devise a JADAS
version for sJIA. In the study plan, a modification of the
original instrument has been envisioned to enable the
quantification of extraarticular symptoms, with an approach
similar to that of the systemic feature scores reported in Table
1. A key objective of the project is the establishment of the
cutoffs in the new score that correspond to the states of
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